Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The VP, U .

S . S. S.

medical launch readiness, execution, and early commercialization success for Dyne’s first approved product. S . Medical Affairs organization and serve as a critical leader capable of delivering excellence in a first-launch, high ‑ visibility environment.

This position plays a critical leadership role in shaping Dyne’s transition from a clinical-stage to a commercial-stage company, serving as a core member of cross-functional launch governance and a trusted strategic advisor to e xecutive l eadership and member of the US Leadership Team (USLT) . S. S.

healthcare providers, payers, patient communities, and other external stakeholders. The VP, U . S .

Medical Affairs is a key member of the Global Medical Affairs Leadership Team and works in close collaboration with Global Medical Affairs, Commercial, Market Access, Clinical Development, Regulatory, and other functions to ensure seamless alignment and execution through approval, launch, and early lifecycle management. S. medical strategy for Dyne’s first commercial product and establish the foundation for future launches in a rapidly evolving rare disease portfolio.

This role is based in Waltham, MA.

Responsibilities

S. S. S.

VP, U.S. Medical Affairs